Although the relationship of the GH/IGF-I axis with NAFLD and sarcopenia are currently under debate, recent mice models fed with a high fat diet for 12 weeks and supplemented with GH or IGF-I have demonstrated that GH and IGF-I supplementation induces significant improvement in both liver steatosis and sarcopenia, indicating that low levels of this factor can represent a severe marker of deterioration in general function of the organism [117]. This evidence concerns the gene GH1 and metabolic dysfunction-associated steatotic liver disease.